U Study to Assess New Drug Treatment for Stuttering in Adults

U Study to Assess New Drug Treatment for Stuttering in Adults

Feb 2, 2006 5:00 PM

A clinical research study is underway at the University of Utah to evaluate the safety and effectiveness of a new medication to treat the symptoms of persistent developmental stuttering (PDS). The U is seeking 10 adults, between the ages of 18 and 65, with PDS to participate in the eight-week trial.

The diagnosis of PDS applies to adults who began stuttering prior to the age of eight and have not outgrown the speech disorder. Approximately three million Americans stutter, or .8 percent of the population, according to Michael Blomgren, Ph.D., co-investigator and assistant professor of communication sciences and disorders at the University of Utah.

Speech therapy is the traditional treatment of choice for stuttering, Blomgren said. Currently, there are no drug treatments approved for stuttering, so this clinical study is an exciting opportunity for us to possibly understand the cause of stuttering.

The Mood Disorders Clinic at University Hospital & Clinics along with the Department of Communications Disorders in the U's College of Health is one of 12 sites across the country to participate in this study. At the study's conclusion, participants may participate in a 12-month extension.

Stuttering is a speech disorder characterized by repetitions, prolongations of sounds or abnormal stoppages of sounds and syllables. There may also be unusual facial and body movements associated with the effort to speak.

For more information on the study, call (801) 585-6663 or visit the Web site: www.stutteringstudy.com.


Michael Blomgren, College of Health,


Chantelle Turner, Health Sciences Public Affairs Office,


# # #

Visit our News Archive for a complete list of previous News.